Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Safety and efficacy results of a phase iv safety-monitoring study of icotinib in treating advanced non-small cell lung cancer

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Presentation
  • By: DING, Lieming (Betta Pharmaceuticals Co.,Ltd., Hangzhou, China)
  • Co-author(s): Tan, Fenlai (Betta Pharmaceuticals Co.,Ltd., Hangzhou, China)
    Han, Baohui (Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China)
    Hu, Xingsheng (Department of Medical Oncology, Cancer Institute/Hospital, CAMS & PUMC, Beijing, China)
    Zhang, Yiping (Zhejiang Cancer Hospital, Hangzhou, China)
    Liu, Xiguang (The Affiliated Hospital of Qingdao University, Qingdao, China)
    Sun, Yan (Department of Medical Oncology, Cancer Institute/Hospital, CAMS & PUMC, Beijing, China)
  • Abstract:

    Background: Icotinib was approved as a target therapy drug by China Food and Drug Administration for treating advanced non-small-cell lung cancer (NSCLC) based on its phase III ICOGEN trial. A safety-monitoring study was then conducted to assess the safety and efficacy of icotinib in a broader range of NSCLC patients. Methods: In this phase IV..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses